Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension Abstract Purpose: To determine circulating levels of the soluble TNF-like weak inducer of apoptosis (sTWEAK)and its association with demographic and biochemical parameters in a young group of patients with newly diagnosed and never treated hypertension.
Hypertension is a major risk factor for atherosclerosis and cardiovascular disease (CVD) [1] . Various mechanism have been suggested for hypertension related increases in the risk of CVD, with endothelial dysfunction (ED) and in ammation being the moststudied conditions [1, 2] . Vascular endothelium plays a pivotal role in the regulation of vascular tone and maintenance of cardiovascular homeostasis by releasing various vasoactive factors. Endothelial functions are in uenced by systemic in ammation at the very early stages.
TNF-like weak inducer of apoptosis (TWEAK, TNFSF12) is one of the members of the TNF superfamily [3] .
e human TWEAK gene encodes a 249-amino acid type II transmembrane glycoprotein (30 kD) . TWEAK is a multifunctional cytokine, which regulates cell growth, migration and survival. Moreover, TWEAK activates the nuclear factor kappa B signaling pathway and induces expression of cell adhesion molecules and di erent proin ammatory cytokines [4, 5] . AlteredsTWEAK plasma levels are associated with aggravation of the ED and increased mortality risk [6] . Similarly, reduced sTWEAK levels have been reported in patients with subclinical atherosclerosis, which is accelerated in the presence of vascular in ammation [7, 8] .
Asymmetrical dimethyl arginine (ADMA) is a naturally occurring cellular product that is a competitive endogenous inhibitor of nitric oxide (NO) synthase [9] . Overproduced ADMA blocks the bene cial actions of NO on cellular functions. Recent studies have clearly shown that altered synthesis of ADMA is strongly associated with derangements of endothelial functions [20] , making it a successful marker of ED especially for research purposes [11] . ED is an early, perhaps initiating, event in the pathogenesis of CVD and has been shown to be present in patients with essential hypertension [12] .
In the present speci cally designed study, we aimed to investigate serum sTWEAK levels [6, 13] , and determine the association with demographic characteristics and with ED, as determined by circulating ADMA measurement.
Materials and Methods

Patients and controls
A total of 51 young males (mean age: 21.7±1.4 years) with newly diagnosed, primary and untreated hypertension were enrolled along with37age-and body mass index-(BMI) matched healthy controls (mean age: 22.5 ± 1.9 years). None of the patients or controls had family history of hypertension or diabetes mellitus.
e secondary causes of hypertension were eliminated by medical history, physical examination and laboratory measurements where necessary. People with a history of metabolic or in ammatory disorders, dyslipidemia (low-density lipoprotein-LDL cholesterol levels >130 mg/dl, triglycerides >150mg/dl), obesity (BMI>30 kg/m 2 ), clinical evidence for CVD, rheumatic disease, renal failure, hepatic disease, thyroid dysfunction, concomitant medications (including herbal remedies and over-the-counter drugs) and regular alcohol or drug consumption were not included in the study. e local ethics committee of Gulhane School of Medicine approved the study protocol and written informed consent was obtained from each participant.
De nition of Hypertension
Blood pressure was measured with an appropriate arm cu and a mercury column sphygmomanometer a er a resting period of at least 5 min from the right arm. e same physician performed all measurements, and the mean of the two sitting measurements on di erent days was used as the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the patients and controls. As a routine practice for the diagnosis of hypertension in the youth in our clinic, 24hour ambulatory blood pressure was monitoredin all patients and controls. Hypertension was de ned as SBP greater than 140 mmHg or DBP greater than 90 mmHg on repeated manual measurements.
Demographic and Biochemical Parameters
Weight (in kilograms) and height (in centimeters) were measured and BMI was calculated as body weight/height 2 (kg/m 2 ).Waist circumference was measured around the line in the middle of the lower rib and the anterior superior iliac spine. For biochemical analyses, all blood samples were drawn in the morning a er at least 10 h of fasting. e samples were promptly centrifuged and the plasma and serum were separated and stored at −80° C. All plasma samples were run in the same assay. Fasting plasma glucose, total cholesterol (TC), triglyceride and high-density lipoprotein cholesterol (HDL-C) levels were measured by the enzymatic colorimetric method with an Olympus AU2700 auto analyzer using reagents from Olympus Diagnostics (GmbH, Hamburg, Germany). Low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald's Formula [14] . ADMA was measured in plasma by EIA (ADMA direct ELISA Kit, Lot Nr. K7828, Immundiagnostik AG, Bensheim, Germany) (minimum detectable concentration= 0.05 μmol/L). sTWEAK was measured in serum by ELISA kit in duplicate (Bender MedSystems, Lot Nr. BMS2006INST, Vienna, Austria). e calculated overall intraassay and inter-assay coe cient of variation for sTWEAK 7 
Results
Demographic characteristics and biochemical results of the study groups are shown in Table 1 . Patients and the controls were matched for age and BMI. Mean SBP and DBP were 149.8±5.65 and 93.4±3.4 mmHgin the patient group.Because the work was designed to study increased blood pressure that cannot be described as long standing or chronic, the participants were enrolled only when they were young but had sustained elevations in both systolic and diastolic pressures. A control group, consisting of healthy subjects, had a mean SBP of 124.2±6.4mmHgand DBP of 78.24±5. cholesterol, LDL-cholesterol, urea, creatinine, uric acid, aspartate aminotransferase, alanine aminotransferase and hemoglobin levels, white blood cell counts, mean corpuscular volume and mean platelet volumes were similar.
Mean circulating sTWEAK levels were signi cantly lower in the patient group compared to the control group (882.6±228.9 vs.1060.18±231.7 μmol/L, p=0,001) (Figure 1 ). On the other hand, mean plasma ADMA levels were signicantly higher in the patient group (0.837±0.34 vs.0.317±0.25 μmol/L, p<0.001) (Figure 2 ). SBP and DBP correlated negatively with the serum sTWEAK level (r=-0.301, p=0.005, and r=-0.279, p=0.009, respectively). ere was a strong, signi cant positive correlation between SBP, DBP and plasma ADMA level(r=0.734, p<0.001, and r=0.733, p<0.001, respectively). A er adjustment for age, BMI, waist circumference, total cholesterol, triglyceride and fasting plasma glucose, the strength of the association ofSBP to sTWEAK and ADMA levels did not reduce (p=0.048 and p<0.001, respectively).No correlation was found between serum sTWEAK and plasma ADMA levels.
Discussion
e current study is the rst to examine serum sTWEAK and plasma ADMA levels together in young patients with a recent diagnosis of hypertension. All patients were male and a group of appropriate healthy controls was speci cally formed. Such a scenario has the advantage of observing the alterations in circulating hormone or protein levels due mostly to increased blood pressure but not to chronic systemic changes. Serum levels of several cytokines or adipokines in people with hypertension, dyslipidemia or obesity have been reported to change according to age associated comorbidities or gender [15] .
In the present study, although the decreased serum TWEAK levels were accompanied by an increase in circulating plasma ADMA levels, a statistical correlation between the two alterations could not be detected. A high plasma ADMA level is accepted as an indicator of ED [11] ,which can ideally be identi ed by ow mediated dilation(FMD) [16] [17] [18] .Increased circulating ADMA in people with hypertension was previously reported by Böger [19] . erefore, the present results simply suggest that dysregulated synthesis and secretion of sTWEAK is not involved in the mechanism of impaired endothelial functions. Whether di erent results could be observed if ED was measured by FMD is unclear. In a recent study, treatment with anti-hypertensive medication was found to improve FMD and normalize proteinuria, pentraxin3 (PTX3) and sTWEAK in diabetic chronic kidney disease stage 1 patients with hypertension [20] .
e newly diagnosed hypertensives in the present study provide the advantage of studying "null" hypertensivespatients who had no drug treatment before -and allows for the observation of early changes in serum chemical markers, although the duration of the in ammation is not known.
Dysfunction of the vascular endothelium plays an important role in initiation and progression of atherosclerosis [21] .
e most important endothelium-derived relaxing factor is NO, which may be released a er stimulation by endogenous and pharmacologic agonists and physical stimuli such as owmediated shear stress [22] [23] [24] . It is well known that endothelium-dependent vasodilation is impaired in forearm vasculature of hypertensive patients, and is responsible for the increase in vascular resistance and the vascular structural changes [25] . It seems that ED contributes to the pathogenesis of hypertension by altering the balance between vasodilator and vasoconstrictor forces on the vasculature. is abnormality, probably multifactorial, may be related to a diminished NO bioavailability that follows a reduction of NO synthesis and/or its increased inactivation by oxidative stress. us, in patients with hypertension and other cardiovascular risk factors, ED characterized by decreased endothelium-dependent vasodilation and proin ammatory, proliferative and procoagulatory factors that promote atherosclerosis may be considered the initial modi cation [1] . In accordance with the previous studies that reported high ADMA levels in middle-aged hypertensives [26, 27] , increased plasma ADMA levels were found in our young hypertensive group compared with matched controls. Circulating ADMA levels, as a novel cardiovascular risk factor, are increased in patients with systemic atherosclerosis, hypercholesterolemia, essential hypertension and end-stage renal failure [28] . ese diseases are linked to an impairment of the NO-pathway and endothelial functions [11] . Several prospective studies, in which cardiovascular disease surrogate endpoints were used, supplied evidence of a pathophysiological role of ADMA in the pathogenesis of vascular dysfunction and cardiovascular disease in humans. Moreover, high plasma ADMA level was found to be associated with carotid atherosclerosis in a study with healthy human subjects [29] . e present study shows that circulating ADMA is increased in the very early stages of clinically established hypertension. is may be one explanation of the fact that a high ADMA blood level is a strong predictor of future CVD.
Circulating sTWEAK levels have been shown to be reduced in some chronic conditions. Lower serum sTWEAK has been reported in subjects with subclinical atherosclerosis, diabetics and chronic kidney disease patients [8, 20, 30] . Moreover in chronic kidney disease, serum sTWEAK appeared to be negatively associated with ED, and to all-cause and cardiovascular mortality in subjects undergoing hemodialysis [6, 31] . In patients with chronic heart failure, a reduced serum sTWEAK level was a predictor of an adverse prognosis [32, 33] . ese ndings may be explained, at least in part, by the presence of a newly discovered scavenger receptor of sTWEAK, CD163, which can sequester and degrade sTWEAK under proin ammatory conditions [34] . Expression of CD163 has also been shown to be upregulated in chronic kidney disease patients [35] . ese data suggest that one reason for reduced sTWEAK serum level in our young patients with recent onset primary hypertension may be the scavenging e ect of CD163. On the other hand, our study showed that alterations in the synthesis and secretion of TWEAK protein occurs, in contrast to chronic conditions stated above, very early in the period of blood pressure increase.
ere are a couple of limitations in the present study. First, the number of patient population is too small to represent all hypertensive patients, although this was not the primary aim of the study. Second, to make further comments on the possible role of sTWEAK in the mechanism of hypertension, data related to other measures of insulin sensitivity, in ammation and ED such as HOMA calculation, hs-CRP and FMD test, would have to be measured.
In conclusion, young patients with newly diagnosed and never treated primary hypertension have lower level of circulating sTWEAK compared to healthy controls. Further evaluation of the associations among TWEAK, ED and other measures of atherosclerosis may be of bene t in order to better understand the pathophysiology of hypertension and to establish more e ective treatment options.
